Related Experiment Videos

Prognostic value of high-sensitivity C-reactive protein in patients with chronic heart failure

Chuncai Xue1, Ying Feng, Jinshan Wo

  • 1Department of Cardiology, The People's Hospital of Binzhou City. Binzhou City, 256610, Shandong, China. xuechc@yahoo.com.cn

The New Zealand Medical Journal
|December 6, 2006
PubMed

Insights

High-sensitivity C-reactive protein (hsCRP) is elevated in chronic heart failure (CHF) patients and predicts cardiac events. This biomarker, along with troponin T and reduced ejection fraction, indicates higher risk in CHF patients.

Area of Science:

  • Cardiology
  • Biomarkers
  • Heart Failure Research

Background:

  • Chronic heart failure (CHF) is a complex condition with significant morbidity and mortality.
  • Identifying reliable prognostic markers is crucial for managing CHF patients.
  • Inflammation plays a role in the pathophysiology of heart failure.

Purpose of the Study:

  • To investigate the prognostic value of high-sensitivity C-reactive protein (hsCRP) in patients with chronic heart failure (CHF).
  • To assess the relationship between hsCRP levels and cardiac events in CHF patients.
  • To determine if hsCRP is an independent predictor of adverse cardiac outcomes.

Main Methods:

  • Serum hsCRP and cardiac troponin T (TNT) levels were measured in 128 CHF patients and 25 healthy controls.
  • Cardiac events were defined as cardiac death or rehospitalization for worsening heart failure.
  • Multivariate Cox regression analysis was used to identify independent predictors of cardiac events.

Main Results:

  • hsCRP and TNT levels were significantly higher in CHF patients compared to controls and increased with CHF severity.
  • Patients experiencing cardiac events had higher hsCRP and TNT levels and lower left ventricular ejection fraction (LVEF).
  • hsCRP, TNT, and LVEF were independent predictors of cardiac events in CHF patients.

Conclusions:

  • Elevated serum hsCRP concentrations are observed in CHF patients and correlate with disease severity.
  • hsCRP is an independent significant predictor of cardiac events in patients with chronic heart failure.
  • hsCRP may serve as a valuable prognostic biomarker in the management of CHF.
Abstract

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...